Gilead Sciences (FRA:GIS) 3-Year EPS without NRI Growth Rate : 24.50% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Gilead Sciences 3-Year EPS without NRI Growth Rate?

Gilead Sciences's EPS without NRI for the three months ended in Dec. 2023 was €1.58.

During the past 12 months, Gilead Sciences's average EPS without NRI Growth Rate was 13.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 24.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 4.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Gilead Sciences was 120.20% per year. The lowest was -50.90% per year. And the median was 4.90% per year.

Competitive Comparison of Gilead Sciences's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - General subindustry, Gilead Sciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's 3-Year EPS without NRI Growth Rate falls into.

Gilead Sciences 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Gilead Sciences (FRA:GIS) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Gilead Sciences 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (FRA:GIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (FRA:GIS) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.